Table 1 Overview of the literature on the (significant) relation between biomarker and radiographic progression

Syversen et al.¹⁰

RA ≤4 yr

136

C2C (baseline serum)

SHS rapid >1 vs. slow <1

NS

(radiographic progression per yr, progression change baseline to 5 or 10 yr)

Mullan et al.⁹

RA

45

C2C (baseline,1, 3, 6, 9,12-mo serum)

C2C ↑ at 1, 3 mo

PsA

17

C1,2C

SHS rapid >1.5 vs. slow <1.5

C1,2C ↑ at 1, 3 mo

(mean 11 yr, DAS28 >3.2)

CPII

(radiographic progression at 1 yr)

NS

ΔCOL (ΔC2C + ΔC1,2C + ΔCPII)

ΔCOL ↑ at 1, 3, 6, 9 mo

Verstappen et al.¹¹

RA ≤1 yr

87

C2C (1, 2, 3, 4-yr serum)

C2C ↑

C1,2C

66 ^th = SHS >7.4 vs. 33 ^rd percentile = SHS <2.3

C1,2C ↑

CS846

(radiographic progression over 4-yr span)

CS846 ↑

CPII

NS

Ishiguro et al.⁷

RA

63

C2C (knee SF)

Mild vs. moderate vs. severe RA

NS

(mean 10 yr)

CS846

Mild vs. moderate RA

CS846 ↓

CPII

Mild vs. moderate vs. severe RA

NS

(Larsen score: 0, 1 = mild; 2, 3 = moderate; 4, 5 = severe)

Mansson et al.⁸

RA ≤2 yr

18

CS846 (baseline serum)

Rapid vs. slow hip-joint radiographic progression

CS846 ↓

CPII

(Larsen score: rapid = 46; slow = 4 at 2 yr)

NS